Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Warren H Fong

Showing results (1-10 of 2) with videos related to

Pageof 1
Sort By:
JAMA Oncology|March 12, 2016
340B Drug Pricing Program ReformWarren H Fong
Cancer Biotherapy & Radiopharmaceuticals|June 30, 2011
Should high-dose interleukin-2 still be the preferred treatment for patients with metastatic renal cell cancer?Robert O Dillman, Neil M Barth, Louis A VanderMolen, et al.
Pageof 1

Showing results (1-10 of 2) with videos related to

Sort By:
Pageof 1
JAMA Oncology|March 12, 2016
340B Drug Pricing Program ReformWarren H Fong
Cancer Biotherapy & Radiopharmaceuticals|June 30, 2011
Should high-dose interleukin-2 still be the preferred treatment for patients with metastatic renal cell cancer?Robert O Dillman, Neil M Barth, Louis A VanderMolen, et al.
Pageof 1